{"studyId":"blca_iatlas_imvigor210_2017","cancerTypeId":"blca","name":"Metastatic Bladder Urothelial Carcinoma (IMvigor210 Phase II Trial, ESMO Open. 2024) - iAtlas Harmonized","description":"Whole-exome sequencing and neoantigen landscape analysis of 347 metastatic bladder urothelial carcinomas and their matched normals, generated from a phase II trial of atezolizumab monotherapy in cisplatin-ineligible and platinum-pretreated patients. The reprocessing of raw sequencing data is coordinated by <a href=\"https://cri-iatlas.org/\">CRI iAtlas</a>.","publicStudy":true,"pmid":"39642637,27939400","citation":"Rosenberg et al. ESMO Open 2024","groups":"","status":1,"importDate":"2026-02-11 00:57:09","allSampleCount":347,"sequencedSampleCount":242,"cnaSampleCount":0,"mrnaRnaSeqSampleCount":347,"mrnaRnaSeqV2SampleCount":0,"mrnaMicroarraySampleCount":0,"miRnaSampleCount":0,"methylationHm27SampleCount":0,"rppaSampleCount":0,"massSpectrometrySampleCount":0,"completeSampleCount":0,"referenceGenome":"hg38","treatmentCount":0,"structuralVariantCount":0,"cancerType":{"id":"blca","name":"Bladder Urothelial Carcinoma","dedicatedColor":"Yellow","shortName":"BLCA","parent":"bladder"},"readPermission":true,"resourceCounts":[]}